Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion_老虎社区_美港股上老虎

Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion

Reuters2021-11-18

Danish drugmaker Novo Nordisk will buy Dicerna Pharmaceuticals Inc for $3.3 billion in cash, the U.S. drug developer said on Thursday. The deal for $38.25 per share represents a premium of 79.7% to ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

Rustyx
·2021-11-18
Like pls
回复
2
举报
收起
- JennyLim:
  Ok
  2021-11-19
  回复
  举报
xxbbew
·2021-11-18
Like
回复
2
举报
收起
- Tedam:
  done
  2021-11-18
  回复
  举报
Jstan
·2021-11-18
Lije pls
回复
1
举报
收起
- xxbbew:
  Ok
  2021-11-18
  回复
  举报
W00dy
·2021-11-18
Like pls
回复
3
举报
收起
- Jstan:
  like too
  2021-11-18
  回复
  举报
Yugi
·2021-11-18
Lk
回复
3
举报
收起
- Yugi:
  .
  2021-11-18
  回复
  举报
Chenmz
·2021-11-18
.
回复
4
举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1118881918?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-18 20:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118881918","market":"us","top_or_hot":-1,"title":"Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion","media":"Reuters","content":"<div>\n<p>Danish drugmaker Novo Nordisk will buy Dicerna Pharmaceuticals Inc for $3.3 billion in cash, the U.S. drug developer said on Thursday.\nThe deal for $38.25 per share represents a premium of 79.7% to ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/denmarks-novo-nordisk-buy-dicerna-pharma-33-billion-2021-11-18/\">网页链接</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDenmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-18 20:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/denmarks-novo-nordisk-buy-dicerna-pharma-33-billion-2021-11-18/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Danish drugmaker Novo Nordisk will buy Dicerna Pharmaceuticals Inc for $3.3 billion in cash, the U.S. drug developer said on Thursday.\nThe deal for $38.25 per share represents a premium of 79.7% to ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/denmarks-novo-nordisk-buy-dicerna-pharma-33-billion-2021-11-18/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/denmarks-novo-nordisk-buy-dicerna-pharma-33-billion-2021-11-18/","article_id":"1118881918","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118881918","pubTimestamp":1637239194,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"Danish drugmaker Novo Nordisk will buy Dicerna Pharmaceuticals Inc for $3.3 billion in cash, the U.S","collect":0,"end_time":0,"defaultTopTitle":"reuters.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"丹麦诺和诺德将以33亿美元收购迪塞纳制药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":0.9},"content_text":"Danish drugmaker Novo Nordisk will buy Dicerna Pharmaceuticals Inc for $3.3 billion in cash, the U.S. drug developer said on Thursday.\nThe deal for $38.25 per share represents a premium of 79.7% to Dicerna's closing price on Wednesday.\nThe two companies have been in a research collaboration since 2019 to develop multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases.\nNovo Nordisk expects to initiate clinical development of the first investigational therapeutic to emerge from this collaboration in 2022.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":876091290,"gmtCreate":1637241343774,"gmtModify":1637241343928,"author":{"id":"3582065337930537","authorId":"3582065337930537","name":"Rustyx","avatar":"https://static.tigerbbs.com/8289642873b5ec03fda36cf3e70cea6d","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3582065337930537","idStr":"3582065337930537"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/876091290","repostId":1118881918,"repostType":4,"repost":{"id":"1118881918","kind":"news","pubTimestamp":1637239194,"share":"https://www.laohu8.com/m/news/1118881918?lang=zh_CN&edition=full","pubTime":"2021-11-18 20:39","market":"us","language":"en","title":"Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion<blockquote>丹麦诺和诺德将以33亿美元收购Dicerna Pharma</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1118881918","media":"Reuters","summary":"Danish drugmaker Novo Nordisk will buy Dicerna Pharmaceuticals Inc for $3.3 billion in cash, the U.S","content":"<p>Danish drugmaker Novo Nordisk&nbsp;will buy Dicerna Pharmaceuticals Inc&nbsp;for $3.3 billion in cash, the U.S. drug developer said on Thursday.</p><p><blockquote>丹麦制药商诺和诺德周四表示，将以33亿美元现金收购Dicerna Pharmaceuticals Inc.。</blockquote></p><p> The deal for $38.25 per share represents a premium of 79.7% to Dicerna's closing price on Wednesday.</p><p><blockquote>该交易每股38.25美元，较Dicerna周三收盘价溢价79.7%。</blockquote></p><p> The two companies have been in a research collaboration since 2019 to develop multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases.</p><p><blockquote>自2019年以来，两家公司一直在进行研究合作，开发多种临床候选药物，用于治疗慢性肝病、非酒精性脂肪性肝炎(NASH)、2型糖尿病、肥胖症和罕见疾病等疾病。</blockquote></p><p> Novo Nordisk expects to initiate clinical development of the first investigational therapeutic to emerge from this collaboration in 2022.</p><p><blockquote>诺和诺德预计将于2022年启动此次合作产生的首个研究治疗药物的临床开发。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion<blockquote>丹麦诺和诺德将以33亿美元收购Dicerna Pharma</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDenmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion<blockquote>丹麦诺和诺德将以33亿美元收购Dicerna Pharma</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-18 20:39</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Danish drugmaker Novo Nordisk&nbsp;will buy Dicerna Pharmaceuticals Inc&nbsp;for $3.3 billion in cash, the U.S. drug developer said on Thursday.</p><p><blockquote>丹麦制药商诺和诺德周四表示，将以33亿美元现金收购Dicerna Pharmaceuticals Inc.。</blockquote></p><p> The deal for $38.25 per share represents a premium of 79.7% to Dicerna's closing price on Wednesday.</p><p><blockquote>该交易每股38.25美元，较Dicerna周三收盘价溢价79.7%。</blockquote></p><p> The two companies have been in a research collaboration since 2019 to develop multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases.</p><p><blockquote>自2019年以来，两家公司一直在进行研究合作，开发多种临床候选药物，用于治疗慢性肝病、非酒精性脂肪性肝炎(NASH)、2型糖尿病、肥胖症和罕见疾病等疾病。</blockquote></p><p> Novo Nordisk expects to initiate clinical development of the first investigational therapeutic to emerge from this collaboration in 2022.</p><p><blockquote>诺和诺德预计将于2022年启动此次合作产生的首个研究治疗药物的临床开发。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/denmarks-novo-nordisk-buy-dicerna-pharma-33-billion-2021-11-18/\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVO":"诺和诺德"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/denmarks-novo-nordisk-buy-dicerna-pharma-33-billion-2021-11-18/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118881918","content_text":"Danish drugmaker Novo Nordisk will buy Dicerna Pharmaceuticals Inc for $3.3 billion in cash, the U.S. drug developer said on Thursday.\nThe deal for $38.25 per share represents a premium of 79.7% to Dicerna's closing price on Wednesday.\nThe two companies have been in a research collaboration since 2019 to develop multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases.\nNovo Nordisk expects to initiate clinical development of the first investigational therapeutic to emerge from this collaboration in 2022.","news_type":1,"symbols_score_info":{"NVO":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6632605,"gmtCreate":1637251693473,"gmtModify":1637251693576,"authorId":3564644209488014,"author":{"id":3564644209488014,"idStr":"3564644209488014","authorId":3564644209488014,"name":"JennyLim","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":876091290,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":876006878,"gmtCreate":1637240388127,"gmtModify":1637240388260,"author":{"id":"3573467106982618","authorId":"3573467106982618","name":"xxbbew","avatar":"https://static.tigerbbs.com/39068f2ebe66e4e0b64c90ad557577c0","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3573467106982618","idStr":"3573467106982618"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/876006878","repostId":1118881918,"repostType":4,"repost":{"id":"1118881918","kind":"news","pubTimestamp":1637239194,"share":"https://www.laohu8.com/m/news/1118881918?lang=zh_CN&edition=full","pubTime":"2021-11-18 20:39","market":"us","language":"en","title":"Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion<blockquote>丹麦诺和诺德将以33亿美元收购Dicerna Pharma</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1118881918","media":"Reuters","summary":"Danish drugmaker Novo Nordisk will buy Dicerna Pharmaceuticals Inc for $3.3 billion in cash, the U.S","content":"<p>Danish drugmaker Novo Nordisk&nbsp;will buy Dicerna Pharmaceuticals Inc&nbsp;for $3.3 billion in cash, the U.S. drug developer said on Thursday.</p><p><blockquote>丹麦制药商诺和诺德周四表示，将以33亿美元现金收购Dicerna Pharmaceuticals Inc.。</blockquote></p><p> The deal for $38.25 per share represents a premium of 79.7% to Dicerna's closing price on Wednesday.</p><p><blockquote>该交易每股38.25美元，较Dicerna周三收盘价溢价79.7%。</blockquote></p><p> The two companies have been in a research collaboration since 2019 to develop multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases.</p><p><blockquote>自2019年以来，两家公司一直在进行研究合作，开发多种临床候选药物，用于治疗慢性肝病、非酒精性脂肪性肝炎(NASH)、2型糖尿病、肥胖症和罕见疾病等疾病。</blockquote></p><p> Novo Nordisk expects to initiate clinical development of the first investigational therapeutic to emerge from this collaboration in 2022.</p><p><blockquote>诺和诺德预计将于2022年启动此次合作产生的首个研究治疗药物的临床开发。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion<blockquote>丹麦诺和诺德将以33亿美元收购Dicerna Pharma</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDenmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion<blockquote>丹麦诺和诺德将以33亿美元收购Dicerna Pharma</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-18 20:39</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Danish drugmaker Novo Nordisk&nbsp;will buy Dicerna Pharmaceuticals Inc&nbsp;for $3.3 billion in cash, the U.S. drug developer said on Thursday.</p><p><blockquote>丹麦制药商诺和诺德周四表示，将以33亿美元现金收购Dicerna Pharmaceuticals Inc.。</blockquote></p><p> The deal for $38.25 per share represents a premium of 79.7% to Dicerna's closing price on Wednesday.</p><p><blockquote>该交易每股38.25美元，较Dicerna周三收盘价溢价79.7%。</blockquote></p><p> The two companies have been in a research collaboration since 2019 to develop multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases.</p><p><blockquote>自2019年以来，两家公司一直在进行研究合作，开发多种临床候选药物，用于治疗慢性肝病、非酒精性脂肪性肝炎(NASH)、2型糖尿病、肥胖症和罕见疾病等疾病。</blockquote></p><p> Novo Nordisk expects to initiate clinical development of the first investigational therapeutic to emerge from this collaboration in 2022.</p><p><blockquote>诺和诺德预计将于2022年启动此次合作产生的首个研究治疗药物的临床开发。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/denmarks-novo-nordisk-buy-dicerna-pharma-33-billion-2021-11-18/\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVO":"诺和诺德"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/denmarks-novo-nordisk-buy-dicerna-pharma-33-billion-2021-11-18/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118881918","content_text":"Danish drugmaker Novo Nordisk will buy Dicerna Pharmaceuticals Inc for $3.3 billion in cash, the U.S. drug developer said on Thursday.\nThe deal for $38.25 per share represents a premium of 79.7% to Dicerna's closing price on Wednesday.\nThe two companies have been in a research collaboration since 2019 to develop multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases.\nNovo Nordisk expects to initiate clinical development of the first investigational therapeutic to emerge from this collaboration in 2022.","news_type":1,"symbols_score_info":{"NVO":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6629833,"gmtCreate":1637240559473,"gmtModify":1637240559577,"authorId":3574663138666653,"author":{"id":3574663138666653,"idStr":"3574663138666653","authorId":3574663138666653,"name":"Tedam","avatar":"https://static.tigerbbs.com/b03558df0abaa80f9e6b141bb1e3d38e","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":876006878,"type":1,"supId":0,"prevId":0,"content":"<u>done</u>","text":"<u>done</u>","html":"<u>done</u>"}],"langContent":"CN"},{"id":876003376,"gmtCreate":1637239975740,"gmtModify":1637239975932,"author":{"id":"3570885355172302","authorId":"3570885355172302","name":"Jstan","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3570885355172302","idStr":"3570885355172302"},"htmlText":"Lije pls","listText":"Lije pls","text":"Lije pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/876003376","repostId":1118881918,"repostType":4,"repost":{"id":"1118881918","kind":"news","pubTimestamp":1637239194,"share":"https://www.laohu8.com/m/news/1118881918?lang=zh_CN&edition=full","pubTime":"2021-11-18 20:39","market":"us","language":"en","title":"Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion<blockquote>丹麦诺和诺德将以33亿美元收购Dicerna Pharma</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1118881918","media":"Reuters","summary":"Danish drugmaker Novo Nordisk will buy Dicerna Pharmaceuticals Inc for $3.3 billion in cash, the U.S","content":"<p>Danish drugmaker Novo Nordisk&nbsp;will buy Dicerna Pharmaceuticals Inc&nbsp;for $3.3 billion in cash, the U.S. drug developer said on Thursday.</p><p><blockquote>丹麦制药商诺和诺德周四表示，将以33亿美元现金收购Dicerna Pharmaceuticals Inc.。</blockquote></p><p> The deal for $38.25 per share represents a premium of 79.7% to Dicerna's closing price on Wednesday.</p><p><blockquote>该交易每股38.25美元，较Dicerna周三收盘价溢价79.7%。</blockquote></p><p> The two companies have been in a research collaboration since 2019 to develop multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases.</p><p><blockquote>自2019年以来，两家公司一直在进行研究合作，开发多种临床候选药物，用于治疗慢性肝病、非酒精性脂肪性肝炎(NASH)、2型糖尿病、肥胖症和罕见疾病等疾病。</blockquote></p><p> Novo Nordisk expects to initiate clinical development of the first investigational therapeutic to emerge from this collaboration in 2022.</p><p><blockquote>诺和诺德预计将于2022年启动此次合作产生的首个研究治疗药物的临床开发。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion<blockquote>丹麦诺和诺德将以33亿美元收购Dicerna Pharma</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDenmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion<blockquote>丹麦诺和诺德将以33亿美元收购Dicerna Pharma</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-18 20:39</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Danish drugmaker Novo Nordisk&nbsp;will buy Dicerna Pharmaceuticals Inc&nbsp;for $3.3 billion in cash, the U.S. drug developer said on Thursday.</p><p><blockquote>丹麦制药商诺和诺德周四表示，将以33亿美元现金收购Dicerna Pharmaceuticals Inc.。</blockquote></p><p> The deal for $38.25 per share represents a premium of 79.7% to Dicerna's closing price on Wednesday.</p><p><blockquote>该交易每股38.25美元，较Dicerna周三收盘价溢价79.7%。</blockquote></p><p> The two companies have been in a research collaboration since 2019 to develop multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases.</p><p><blockquote>自2019年以来，两家公司一直在进行研究合作，开发多种临床候选药物，用于治疗慢性肝病、非酒精性脂肪性肝炎(NASH)、2型糖尿病、肥胖症和罕见疾病等疾病。</blockquote></p><p> Novo Nordisk expects to initiate clinical development of the first investigational therapeutic to emerge from this collaboration in 2022.</p><p><blockquote>诺和诺德预计将于2022年启动此次合作产生的首个研究治疗药物的临床开发。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/denmarks-novo-nordisk-buy-dicerna-pharma-33-billion-2021-11-18/\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVO":"诺和诺德"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/denmarks-novo-nordisk-buy-dicerna-pharma-33-billion-2021-11-18/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118881918","content_text":"Danish drugmaker Novo Nordisk will buy Dicerna Pharmaceuticals Inc for $3.3 billion in cash, the U.S. drug developer said on Thursday.\nThe deal for $38.25 per share represents a premium of 79.7% to Dicerna's closing price on Wednesday.\nThe two companies have been in a research collaboration since 2019 to develop multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases.\nNovo Nordisk expects to initiate clinical development of the first investigational therapeutic to emerge from this collaboration in 2022.","news_type":1,"symbols_score_info":{"NVO":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6629812,"gmtCreate":1637240392754,"gmtModify":1637240392783,"authorId":3573467106982618,"author":{"id":3573467106982618,"idStr":"3573467106982618","authorId":3573467106982618,"name":"xxbbew","avatar":"https://static.tigerbbs.com/39068f2ebe66e4e0b64c90ad557577c0","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":876003376,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":878777896,"gmtCreate":1637239668128,"gmtModify":1637239685865,"author":{"id":"4089162592476240","authorId":"4089162592476240","name":"W00dy","avatar":"https://static.tigerbbs.com/e321bf45dd05336a6b9f1c27eb0ecde8","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"4089162592476240","idStr":"4089162592476240"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/878777896","repostId":1118881918,"repostType":4,"repost":{"id":"1118881918","kind":"news","pubTimestamp":1637239194,"share":"https://www.laohu8.com/m/news/1118881918?lang=zh_CN&edition=full","pubTime":"2021-11-18 20:39","market":"us","language":"en","title":"Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion<blockquote>丹麦诺和诺德将以33亿美元收购Dicerna Pharma</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1118881918","media":"Reuters","summary":"Danish drugmaker Novo Nordisk will buy Dicerna Pharmaceuticals Inc for $3.3 billion in cash, the U.S","content":"<p>Danish drugmaker Novo Nordisk&nbsp;will buy Dicerna Pharmaceuticals Inc&nbsp;for $3.3 billion in cash, the U.S. drug developer said on Thursday.</p><p><blockquote>丹麦制药商诺和诺德周四表示，将以33亿美元现金收购Dicerna Pharmaceuticals Inc.。</blockquote></p><p> The deal for $38.25 per share represents a premium of 79.7% to Dicerna's closing price on Wednesday.</p><p><blockquote>该交易每股38.25美元，较Dicerna周三收盘价溢价79.7%。</blockquote></p><p> The two companies have been in a research collaboration since 2019 to develop multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases.</p><p><blockquote>自2019年以来，两家公司一直在进行研究合作，开发多种临床候选药物，用于治疗慢性肝病、非酒精性脂肪性肝炎(NASH)、2型糖尿病、肥胖症和罕见疾病等疾病。</blockquote></p><p> Novo Nordisk expects to initiate clinical development of the first investigational therapeutic to emerge from this collaboration in 2022.</p><p><blockquote>诺和诺德预计将于2022年启动此次合作产生的首个研究治疗药物的临床开发。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion<blockquote>丹麦诺和诺德将以33亿美元收购Dicerna Pharma</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDenmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion<blockquote>丹麦诺和诺德将以33亿美元收购Dicerna Pharma</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-18 20:39</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Danish drugmaker Novo Nordisk&nbsp;will buy Dicerna Pharmaceuticals Inc&nbsp;for $3.3 billion in cash, the U.S. drug developer said on Thursday.</p><p><blockquote>丹麦制药商诺和诺德周四表示，将以33亿美元现金收购Dicerna Pharmaceuticals Inc.。</blockquote></p><p> The deal for $38.25 per share represents a premium of 79.7% to Dicerna's closing price on Wednesday.</p><p><blockquote>该交易每股38.25美元，较Dicerna周三收盘价溢价79.7%。</blockquote></p><p> The two companies have been in a research collaboration since 2019 to develop multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases.</p><p><blockquote>自2019年以来，两家公司一直在进行研究合作，开发多种临床候选药物，用于治疗慢性肝病、非酒精性脂肪性肝炎(NASH)、2型糖尿病、肥胖症和罕见疾病等疾病。</blockquote></p><p> Novo Nordisk expects to initiate clinical development of the first investigational therapeutic to emerge from this collaboration in 2022.</p><p><blockquote>诺和诺德预计将于2022年启动此次合作产生的首个研究治疗药物的临床开发。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/denmarks-novo-nordisk-buy-dicerna-pharma-33-billion-2021-11-18/\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVO":"诺和诺德"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/denmarks-novo-nordisk-buy-dicerna-pharma-33-billion-2021-11-18/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118881918","content_text":"Danish drugmaker Novo Nordisk will buy Dicerna Pharmaceuticals Inc for $3.3 billion in cash, the U.S. drug developer said on Thursday.\nThe deal for $38.25 per share represents a premium of 79.7% to Dicerna's closing price on Wednesday.\nThe two companies have been in a research collaboration since 2019 to develop multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases.\nNovo Nordisk expects to initiate clinical development of the first investigational therapeutic to emerge from this collaboration in 2022.","news_type":1,"symbols_score_info":{"NVO":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6629752,"gmtCreate":1637239980071,"gmtModify":1637239980101,"authorId":3570885355172302,"author":{"id":3570885355172302,"idStr":"3570885355172302","authorId":3570885355172302,"name":"Jstan","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":878777896,"type":1,"supId":0,"prevId":0,"content":"like too","text":"like too","html":"like too"}],"langContent":"CN"},{"id":878775985,"gmtCreate":1637239403654,"gmtModify":1637239403806,"author":{"id":"3571564059182465","authorId":"3571564059182465","name":"Yugi","avatar":"https://static.tigerbbs.com/db4e68dadfa83a895d87b4724c779fd6","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3571564059182465","idStr":"3571564059182465"},"htmlText":"Lk","listText":"Lk","text":"Lk","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/878775985","repostId":1118881918,"repostType":4,"repost":{"id":"1118881918","kind":"news","pubTimestamp":1637239194,"share":"https://www.laohu8.com/m/news/1118881918?lang=zh_CN&edition=full","pubTime":"2021-11-18 20:39","market":"us","language":"en","title":"Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion<blockquote>丹麦诺和诺德将以33亿美元收购Dicerna Pharma</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1118881918","media":"Reuters","summary":"Danish drugmaker Novo Nordisk will buy Dicerna Pharmaceuticals Inc for $3.3 billion in cash, the U.S","content":"<p>Danish drugmaker Novo Nordisk&nbsp;will buy Dicerna Pharmaceuticals Inc&nbsp;for $3.3 billion in cash, the U.S. drug developer said on Thursday.</p><p><blockquote>丹麦制药商诺和诺德周四表示，将以33亿美元现金收购Dicerna Pharmaceuticals Inc.。</blockquote></p><p> The deal for $38.25 per share represents a premium of 79.7% to Dicerna's closing price on Wednesday.</p><p><blockquote>该交易每股38.25美元，较Dicerna周三收盘价溢价79.7%。</blockquote></p><p> The two companies have been in a research collaboration since 2019 to develop multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases.</p><p><blockquote>自2019年以来，两家公司一直在进行研究合作，开发多种临床候选药物，用于治疗慢性肝病、非酒精性脂肪性肝炎(NASH)、2型糖尿病、肥胖症和罕见疾病等疾病。</blockquote></p><p> Novo Nordisk expects to initiate clinical development of the first investigational therapeutic to emerge from this collaboration in 2022.</p><p><blockquote>诺和诺德预计将于2022年启动此次合作产生的首个研究治疗药物的临床开发。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion<blockquote>丹麦诺和诺德将以33亿美元收购Dicerna Pharma</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDenmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion<blockquote>丹麦诺和诺德将以33亿美元收购Dicerna Pharma</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-18 20:39</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Danish drugmaker Novo Nordisk&nbsp;will buy Dicerna Pharmaceuticals Inc&nbsp;for $3.3 billion in cash, the U.S. drug developer said on Thursday.</p><p><blockquote>丹麦制药商诺和诺德周四表示，将以33亿美元现金收购Dicerna Pharmaceuticals Inc.。</blockquote></p><p> The deal for $38.25 per share represents a premium of 79.7% to Dicerna's closing price on Wednesday.</p><p><blockquote>该交易每股38.25美元，较Dicerna周三收盘价溢价79.7%。</blockquote></p><p> The two companies have been in a research collaboration since 2019 to develop multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases.</p><p><blockquote>自2019年以来，两家公司一直在进行研究合作，开发多种临床候选药物，用于治疗慢性肝病、非酒精性脂肪性肝炎(NASH)、2型糖尿病、肥胖症和罕见疾病等疾病。</blockquote></p><p> Novo Nordisk expects to initiate clinical development of the first investigational therapeutic to emerge from this collaboration in 2022.</p><p><blockquote>诺和诺德预计将于2022年启动此次合作产生的首个研究治疗药物的临床开发。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/denmarks-novo-nordisk-buy-dicerna-pharma-33-billion-2021-11-18/\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVO":"诺和诺德"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/denmarks-novo-nordisk-buy-dicerna-pharma-33-billion-2021-11-18/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118881918","content_text":"Danish drugmaker Novo Nordisk will buy Dicerna Pharmaceuticals Inc for $3.3 billion in cash, the U.S. drug developer said on Thursday.\nThe deal for $38.25 per share represents a premium of 79.7% to Dicerna's closing price on Wednesday.\nThe two companies have been in a research collaboration since 2019 to develop multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases.\nNovo Nordisk expects to initiate clinical development of the first investigational therapeutic to emerge from this collaboration in 2022.","news_type":1,"symbols_score_info":{"NVO":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6629651,"gmtCreate":1637239410995,"gmtModify":1637239411023,"authorId":3571564059182465,"author":{"id":3571564059182465,"idStr":"3571564059182465","authorId":3571564059182465,"name":"Yugi","avatar":"https://static.tigerbbs.com/db4e68dadfa83a895d87b4724c779fd6","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":878775985,"type":1,"supId":0,"prevId":0,"content":".","text":".","html":"."}],"langContent":"CN"},{"id":878772552,"gmtCreate":1637239368319,"gmtModify":1637239368319,"author":{"id":"3586427480705539","authorId":"3586427480705539","name":"Chenmz","avatar":"https://static.tigerbbs.com/d7186f3ad8a734d83d6dd0f3e25f1e6d","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3586427480705539","idStr":"3586427480705539"},"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878772552","repostId":1118881918,"repostType":4,"repost":{"id":"1118881918","kind":"news","pubTimestamp":1637239194,"share":"https://www.laohu8.com/m/news/1118881918?lang=zh_CN&edition=full","pubTime":"2021-11-18 20:39","market":"us","language":"en","title":"Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion<blockquote>丹麦诺和诺德将以33亿美元收购Dicerna Pharma</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1118881918","media":"Reuters","summary":"Danish drugmaker Novo Nordisk will buy Dicerna Pharmaceuticals Inc for $3.3 billion in cash, the U.S","content":"<p>Danish drugmaker Novo Nordisk&nbsp;will buy Dicerna Pharmaceuticals Inc&nbsp;for $3.3 billion in cash, the U.S. drug developer said on Thursday.</p><p><blockquote>丹麦制药商诺和诺德周四表示，将以33亿美元现金收购Dicerna Pharmaceuticals Inc.。</blockquote></p><p> The deal for $38.25 per share represents a premium of 79.7% to Dicerna's closing price on Wednesday.</p><p><blockquote>该交易每股38.25美元，较Dicerna周三收盘价溢价79.7%。</blockquote></p><p> The two companies have been in a research collaboration since 2019 to develop multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases.</p><p><blockquote>自2019年以来，两家公司一直在进行研究合作，开发多种临床候选药物，用于治疗慢性肝病、非酒精性脂肪性肝炎(NASH)、2型糖尿病、肥胖症和罕见疾病等疾病。</blockquote></p><p> Novo Nordisk expects to initiate clinical development of the first investigational therapeutic to emerge from this collaboration in 2022.</p><p><blockquote>诺和诺德预计将于2022年启动此次合作产生的首个研究治疗药物的临床开发。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion<blockquote>丹麦诺和诺德将以33亿美元收购Dicerna Pharma</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDenmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion<blockquote>丹麦诺和诺德将以33亿美元收购Dicerna Pharma</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-18 20:39</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Danish drugmaker Novo Nordisk&nbsp;will buy Dicerna Pharmaceuticals Inc&nbsp;for $3.3 billion in cash, the U.S. drug developer said on Thursday.</p><p><blockquote>丹麦制药商诺和诺德周四表示，将以33亿美元现金收购Dicerna Pharmaceuticals Inc.。</blockquote></p><p> The deal for $38.25 per share represents a premium of 79.7% to Dicerna's closing price on Wednesday.</p><p><blockquote>该交易每股38.25美元，较Dicerna周三收盘价溢价79.7%。</blockquote></p><p> The two companies have been in a research collaboration since 2019 to develop multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases.</p><p><blockquote>自2019年以来，两家公司一直在进行研究合作，开发多种临床候选药物，用于治疗慢性肝病、非酒精性脂肪性肝炎(NASH)、2型糖尿病、肥胖症和罕见疾病等疾病。</blockquote></p><p> Novo Nordisk expects to initiate clinical development of the first investigational therapeutic to emerge from this collaboration in 2022.</p><p><blockquote>诺和诺德预计将于2022年启动此次合作产生的首个研究治疗药物的临床开发。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/denmarks-novo-nordisk-buy-dicerna-pharma-33-billion-2021-11-18/\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVO":"诺和诺德"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/denmarks-novo-nordisk-buy-dicerna-pharma-33-billion-2021-11-18/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118881918","content_text":"Danish drugmaker Novo Nordisk will buy Dicerna Pharmaceuticals Inc for $3.3 billion in cash, the U.S. drug developer said on Thursday.\nThe deal for $38.25 per share represents a premium of 79.7% to Dicerna's closing price on Wednesday.\nThe two companies have been in a research collaboration since 2019 to develop multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases.\nNovo Nordisk expects to initiate clinical development of the first investigational therapeutic to emerge from this collaboration in 2022.","news_type":1,"symbols_score_info":{"NVO":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":36,"commentSize":6,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}